-$0.36 Earnings Per Share Expected for Clementia Pharmaceuticals (CMTA) This Quarter

Wall Street analysts predict that Clementia Pharmaceuticals (NASDAQ:CMTA) will post ($0.36) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Clementia Pharmaceuticals’ earnings, with estimates ranging from ($0.46) to ($0.29). Clementia Pharmaceuticals posted earnings per share of ($9.54) during the same quarter last year, which indicates a positive year over year growth rate of 96.2%. The business is expected to report its next earnings results on Thursday, August 9th.

On average, analysts expect that Clementia Pharmaceuticals will report full year earnings of ($1.62) per share for the current financial year, with EPS estimates ranging from ($2.00) to ($1.22). For the next financial year, analysts expect that the company will report earnings of ($1.63) per share, with EPS estimates ranging from ($2.05) to ($1.25). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Clementia Pharmaceuticals.

Get Clementia Pharmaceuticals alerts:

Clementia Pharmaceuticals (NASDAQ:CMTA) last released its earnings results on Wednesday, May 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.09).

Several equities analysts have commented on CMTA shares. B. Riley started coverage on shares of Clementia Pharmaceuticals in a research note on Wednesday, March 28th. They issued a “buy” rating and a $25.00 price target on the stock. Zacks Investment Research lowered shares of Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. Finally, ValuEngine raised Clementia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $26.60.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in shares of Clementia Pharmaceuticals by 5.5% during the first quarter. JPMorgan Chase & Co. now owns 744,869 shares of the company’s stock worth $11,285,000 after purchasing an additional 38,572 shares during the period. Artal Group S.A. acquired a new stake in shares of Clementia Pharmaceuticals during the first quarter worth $3,030,000. Sphera Funds Management LTD. lifted its holdings in shares of Clementia Pharmaceuticals by 22.7% during the first quarter. Sphera Funds Management LTD. now owns 200,000 shares of the company’s stock worth $3,030,000 after purchasing an additional 37,000 shares during the period. Birchview Capital LP lifted its holdings in Clementia Pharmaceuticals by 72.7% in the first quarter. Birchview Capital LP now owns 38,000 shares of the company’s stock valued at $576,000 after acquiring an additional 16,000 shares during the period. Finally, Alps Advisors Inc. lifted its holdings in Clementia Pharmaceuticals by 21.0% in the first quarter. Alps Advisors Inc. now owns 40,943 shares of the company’s stock valued at $620,000 after acquiring an additional 7,116 shares during the period. 68.07% of the stock is owned by hedge funds and other institutional investors.

Shares of CMTA stock traded down $0.06 during trading hours on Friday, reaching $18.10. 43,100 shares of the stock were exchanged, compared to its average volume of 63,296. Clementia Pharmaceuticals has a 12-month low of $11.72 and a 12-month high of $20.15. The firm has a market capitalization of $586.15 million and a price-to-earnings ratio of -2.28.

About Clementia Pharmaceuticals

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models.

Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clementia Pharmaceuticals (NASDAQ:CMTA)

Leave a Reply

Your email address will not be published. Required fields are marked *